Safety of COVID-19 revaccination in patients with prior hypersensitivity reactions: a retrospective study
Abstract Background Hypersensitivity reactions (HSR) to the COVID-19 vaccine have been reported. Despite these reactions, revaccination remains essential. Objective This study aims to explore the potential outcomes of COVID-19 revaccination in individuals with prior vaccine-related adverse reactions...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | Tropical Diseases, Travel Medicine and Vaccines |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40794-025-00266-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Background Hypersensitivity reactions (HSR) to the COVID-19 vaccine have been reported. Despite these reactions, revaccination remains essential. Objective This study aims to explore the potential outcomes of COVID-19 revaccination in individuals with prior vaccine-related adverse reactions. Methods A retrospective study was employed with a sample of 225 patients, with HSR regarding COVID-19 vaccines, who were referred to a university hospital. Demographic data, vaccine types and HSR were collected. Results Seventy-seven percent (175/225) of patients were revaccinated post HSR. Out of the 175 patients, 57.1%, 34.2% and 8.5% had a history of HSR in connection to inactivated vaccines, viral vector vaccines, and mRNA vaccines, respectively. Sixty percent were revaccinated with the same type of vaccine and 63.4% received antihistamines and/or anti-leukotriene premedication. After revaccination, 89.1% did not have adverse reactions, while 10.9% had mild reactions. When comparing patients who experienced HSR following COVID-19 revaccination with those who did not exhibit reactions, a significant association among patients with revaccination adverse effects were a revaccination with inactivated vaccines; Sinovac-CoronaVac (P < 0.001), a history of any allergic diseases (P < 0.001) and underlying allergic rhinitis (P = 0.003). Premedication or change of vaccine type did not have an effect to the rate of adverse reactions reported post revaccinations. Conclusions In this study, COVID-19 revaccination in patients with a history of COVID-19 vaccine-related HSRs was generally safe, with most patients tolerating it well. However, individuals with underlying allergic conditions, particularly allergic rhinitis, exhibited a higher incidence of mild reactions, especially following revaccination with an inactivated vaccine. |
|---|---|
| ISSN: | 2055-0936 |